Your browser doesn't support javascript.
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Fidler, Sarah; Fox, Julie; Tipoe, Timothy; Longet, Stephanie; Tipton, Tom; Abeywickrema, Movin; Adele, Sandra; Alagaratnam, Jasmini; Ali, Mohammad; Aley, Parvinder K; Aslam, Suhail; Balasubramanian, Anbhu; Bara, Anna; Bawa, Tanveer; Brown, Anthony; Brown, Helen; Cappuccini, Federica; Davies, Sophie; Fowler, Jamie; Godfrey, Leila; Goodman, Anna L; Hilario, Kathrine; Hackstein, Carl Philipp; Mathew, Moncy; Mujadidi, Yama F; Packham, Alice; Petersen, Claire; Plested, Emma; Pollock, Katrina M; Ramasamy, Maheshi N; Robinson, Hannah; Robinson, Nicola; Rongkard, Patpong; Sanders, Helen; Serafimova, Teona; Spence, Niamh; Waters, Anele; Woods, Danielle; Zacharopoulou, Panagiota; Barnes, Eleanor; Dunachie, Susanna; Goulder, Philip; Klenerman, Paul; Winston, Alan; Hill, Adrian V S; Gilbert, Sarah C; Carroll, Miles; Pollard, Andrew J; Lambe, Teresa; Ogbe, Ane.
  • Fidler S; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Fox J; Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Tipoe T; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK.
  • Longet S; NIHR Guy's and St Thomas' Biomedical Research Centre.
  • Tipton T; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Abeywickrema M; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Adele S; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Alagaratnam J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Ali M; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Aley PK; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Aslam S; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Balasubramanian A; Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Bara A; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Bawa T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Brown A; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Brown H; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Cappuccini F; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK.
  • Davies S; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Fowler J; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Godfrey L; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Goodman AL; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hilario K; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hackstein CP; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Mathew M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Mujadidi YF; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Packham A; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Petersen C; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Plested E; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Pollock KM; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Robinson H; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Robinson N; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Rongkard P; Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Sanders H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Serafimova T; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK.
  • Spence N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Waters A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Woods D; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Zacharopoulou P; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Barnes E; NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Dunachie S; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Goulder P; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Klenerman P; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Winston A; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Hill AVS; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys and St Thomas' NHS Trust, London, UK.
  • Gilbert SC; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Carroll M; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Pollard AJ; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, University of Oxford, Oxford, UK.
  • Lambe T; Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Ogbe A; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Clin Infect Dis ; 2022 Oct 05.
Article in English | MEDLINE | ID: covidwho-2240690
ABSTRACT

BACKGROUND:

People with HIV on antiretroviral therapy with good CD4 T cell counts make effective immune responses following vaccination against SARS-CoV-2. There are few data on longer term responses and the impact of a booster dose.

METHODS:

Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed twelve months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µl. Immune responses to the ancestral strain and variants of concern were measured by anti-spike IgG ELISA, MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, Activation Induced Marker (AIM) assay and T cell proliferation.

FINDINGS:

54 participants received two doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) one year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titres (MSD), ACE-2 inhibition and IgG ELISA results were significantly higher compared to Day 182 titres (P < 0.0001 for all three). SARS-CoV-2 specific CD4+ T cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4 + and CD8+ T cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron.

CONCLUSIONS:

In PWH receiving a third vaccine dose, there were significant increases in B and T cell immunity, including to known VOCs.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid